← All trials
NCT03439436
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 26, 2018
- Primary completion
- May 2, 2018
- Completion date
- May 2, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 140
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Johnson and JohnsonLead sponsor
- I.M. Sechenov First Moscow State Medical UniversityOverall official - principal investigator
- Research Clinical Centre of the Russian Railways, JSCOverall official - principal investigator
- Johnson and JohnsonStudy director
- Pavlov First Saint Petersburg State Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.